These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 26666800)

  • 1. Review: Combination umeclidinium/vilanterol improved health status more than umeclidinium in COPD.
    Stanbrook MB
    Ann Intern Med; 2015 Dec; 163(12):JC10. PubMed ID: 26666800
    [No Abstract]   [Full Text] [Related]  

  • 2. [Fixed combination of long-acting bronchodilators in COPD].
    Steurer J
    Praxis (Bern 1994); 2015 Oct; 104(22):1221. PubMed ID: 26953373
    [No Abstract]   [Full Text] [Related]  

  • 3. Differential pharmacology and clinical utility of emerging combination treatments in the management of COPD--role of umeclidinium/vilanterol.
    Malerba M; Morjaria JB; Radaeli A
    Int J Chron Obstruct Pulmon Dis; 2014; 9():687-95. PubMed ID: 25061288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Umeclidinium/vilanterol fixed-dose combination for COPD.
    Gras J
    Drugs Today (Barc); 2014 Mar; 50(3):231-8. PubMed ID: 24696868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Systematic Review of the Efficacy and Safety of a Fixed-Dose Combination of Umeclidinium and Vilanterol for the Treatment of COPD.
    Rodrigo GJ; Neffen H
    Chest; 2015 Aug; 148(2):397-407. PubMed ID: 25798635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Magnitude of umeclidinium/vilanterol lung function effect depends on monotherapy responses: Results from two randomised controlled trials.
    Donohue JF; Singh D; Munzu C; Kilbride S; Church A
    Respir Med; 2016 Mar; 112():65-74. PubMed ID: 26797016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Umeclidinium bromide and vilanterol in combination for the treatment of chronic obstructive pulmonary disease.
    Kelly E
    Expert Rev Clin Pharmacol; 2014 Jul; 7(4):403-13. PubMed ID: 24909949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary disease: Results of two randomized studies.
    Siler TM; Kerwin E; Sousa AR; Donald A; Ali R; Church A
    Respir Med; 2015 Sep; 109(9):1155-63. PubMed ID: 26117292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New developments in the combination treatment of COPD: focus on umeclidinium/vilanterol.
    Cazzola M; Segreti A; Matera MG
    Drug Des Devel Ther; 2013; 7():1201-8. PubMed ID: 24143077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease.
    Lipson DA; Crim C; Criner GJ; Day NC; Dransfield MT; Halpin DMG; Han MK; Jones CE; Kilbride S; Lange P; Lomas DA; Lettis S; Manchester P; Martin N; Midwinter D; Morris A; Pascoe SJ; Singh D; Wise RA; Martinez FJ
    Am J Respir Crit Care Med; 2020 Jun; 201(12):1508-1516. PubMed ID: 32162970
    [No Abstract]   [Full Text] [Related]  

  • 11. Early and sustained symptom improvement with umeclidinium/vilanterol
    Kerwin EM; Boucot IH; Vogelmeier CF; Maltais F; Naya IP; Tombs L; Jones PW; Lipson DA; Keeley T; Bjermer L
    Ther Adv Respir Dis; 2020; 14():1753466620926949. PubMed ID: 32462979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized controlled trials and real-world observational studies in evaluating cardiovascular safety of inhaled bronchodilator therapy in COPD.
    Kardos P; Worsley S; Singh D; Román-Rodríguez M; Newby DE; Müllerová H
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2885-2895. PubMed ID: 27932872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of verapamil on systemic exposure and safety of umeclidinium and vilanterol: a randomized and open-label study.
    Mehta R; Kelleher D; Preece A; Hughes S; Crater G
    Int J Chron Obstruct Pulmon Dis; 2013; 8():159-67. PubMed ID: 23569370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 28-Day safety and tolerability of umeclidinium in combination with vilanterol in COPD: a randomized placebo-controlled trial.
    Feldman G; Walker RR; Brooks J; Mehta R; Crater G
    Pulm Pharmacol Ther; 2012 Dec; 25(6):465-71. PubMed ID: 22955035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Umeclidinium/vilanterol: a review of its use as maintenance therapy in adults with chronic obstructive pulmonary disease.
    Blair HA; Deeks ED
    Drugs; 2015 Jan; 75(1):61-74. PubMed ID: 25398674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The combination of umeclidinium bromide and vilanterol in the management of chronic obstructive pulmonary disease: current evidence and future prospects.
    Feldman GJ; Edin A
    Ther Adv Respir Dis; 2013 Dec; 7(6):311-9. PubMed ID: 24004659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Umeclidinium-vilanterol inhaler approved for COPD.
    Traynor K
    Am J Health Syst Pharm; 2014 Feb; 71(3):174. PubMed ID: 24429003
    [No Abstract]   [Full Text] [Related]  

  • 18. Population pharmacokinetics of inhaled umeclidinium and vilanterol in patients with chronic obstructive pulmonary disease.
    Goyal N; Beerahee M; Kalberg C; Church A; Kilbride S; Mehta R
    Clin Pharmacokinet; 2014 Jul; 53(7):637-48. PubMed ID: 24756395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Umeclidinium bromide/vilanterol trifenatate, perampanel, and eslicarbazepine acetate.
    Hussar DA; Dharsi N
    J Am Pharm Assoc (2003); 2014; 54(4):450-2, 454-5. PubMed ID: 25063267
    [No Abstract]   [Full Text] [Related]  

  • 20. Dual Bronchodilation with Indacaterol Maleate/Glycopyrronium Bromide Compared with Umeclidinium Bromide/Vilanterol in Patients with Moderate-to-Severe COPD: Results from Two Randomized, Controlled, Cross-over Studies.
    Kerwin E; Ferguson GT; Sanjar S; Goodin T; Yadao A; Fogel R; Maitra S; Sen B; Ayers T; Banerji D
    Lung; 2017 Dec; 195(6):739-747. PubMed ID: 28993871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.